

# **Participation and Demographics**












1.164 certificates issued to date

This education has the potential to impact **250,848 patients** with Atopic Dermatitis on an annual basis.

3.216-6.432 Patients Weekly






#### **Attendee Patient Care Focus: 95%**

2018 Symposium/Simulcast	Date	Attendees	Assessment Participants	Percentage Participants
Baltimore, MD	5/5/18	218	181	83%
Baltimore, MD Simulcast	5/5/18	372	180	48%
Birmingham, AL	5/19/18	195	176	90%
Raleigh, NC	6/16/18	168	139	83%
Virtual Symposium	6/23/18	655	290	44%
Total		1608	966	66%


# **Atopic Dermatitis: New Insights, New Therapies**

## **Learning Gains Across Objectives**



- 65% Improvement: Review and characterize the clinical features of atopic dermatitis (AD).
- 436% Improvement: Discuss the current immuno-pathophysiology of AD.
- 82% Improvement: Identify strategies for comprehensive treatment of atopic dermatitis in pediatric and adult populations.
- 19% Improvement: Evaluate the clinical application of emerging therapies including topical and targeted biologic agents in the management of AD.

### **Learning Domain Analysis**





- Learners improved their proficiency most strongly in the Knowledge and Competence domains (56%-105%).
- Learners substantially (40%) increased their reported Confidence in their ability to manage patients with moderate-to-severe atopic dermatitis.
- In the Practice domain, there was also a substantial (25%) increase in reported intent to use systemic therapy for patients with moderate-to-severe atopic dermatitis.

### 4-Week Retention Analysis

LEARNING RETENTION: Net gains were measured from Pre-Test to the Post Curriculum Assessment (PCA) in all learning domains. Unmatched t-tests showed that the net gains in all domains were significant.

\*significant at the  $p \le 0.05$  level: unmatched data





Score slippage was observed in Knowledge and Competence from Post-Test to PCA. Confidence and practice strategy ratings increased significantly.

> Sanofi Genzyme and Regeneron Grant ID: IME-2017-11894

